Dr. Panayiotis S. Savvides, MD

Dr. Savvides practices at Havasu Regional Medical Center in Lake Havasu City, Arizona, part of Lifepoint Health.

Dr. Savvides' NPI, 1831115385, was assigned on July 15, 2006. Dr. Savvides graduated from University of Athens in 1986. Dr. Savvides' Arizona license number on file is 50329.

Dr. Savvides' primary practice is Havasu Regional Medical Center, at 101 Civic Center Lane, Lake Havasu City, AZ 86403 in Mohave County. The practice phone is (928) 855-8185.

Dr. Savvides' primary practice is Havasu Regional Medical Center in Lake Havasu City, Arizona, part of Lifepoint Health. Dr. Savvides is also affiliated with Mayo Clinic Hospital - Phoenix. The medical group on file is Mayo Clinic Arizona. Dmand AI also links Dr. Savvides to 3 more hospitals and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Savvides practices, 5 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Savvides' primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Savvides is board certified in medical oncology by the American Board of Internal Medicine. Dmand AI has Dr. Savvides' licenses on file in 5 states: Arizona, Hawaii, Colorado, Ohio and Massachusetts.

Dmand AI lists breast cancer, chronic anemia, chronic leukemia, colorectal cancer, fluid and electrolyte imbalances, immune deficiency disease, lung cancer and lymphoma among the conditions Dr. Savvides treats.

CMS data shows 23,749 Medicare services from Dr. Savvides across 32 procedure codes in 2024, for 449 Medicare patients. Medicare paid $584,979 for them. Every service was in an office.

CMS counts 449 Medicare patients who saw Dr. Savvides in 2024. The largest group is 65 to 74, with 198 patients. 75% of them have high cholesterol, and 72% have high blood pressure. 3% are also on Medicaid. Their average risk score is 3.02, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Savvides' median patient age at 75, with 46% women.

In 2024, Dr. Savvides wrote 314 Medicare Part D claims for 79 patients. 67% of them were for generic drugs. CMS names the drug for 231 of them, across 8 drugs with 11 or more claims each, at $795,210 in total drug cost. In 2023, CMS named 371 claims across 9 drugs.

Dr. Savvides accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 20 papers to Dr. Savvides, published from 2009 to 2023. 2011 was the busiest year, with 2. The most frequent topics are Head and Neck Neoplasms, Antineoplastic Combined Chemotherapy Protocols and Carcinoma, Squamous Cell. Dr. Savvides has published most often in Invest New Drugs. Dr. Savvides' most frequent co-authors are Athanassios Argiris, MD, Vinicius Ernani and Matthew M. Cooney, MD.

Dmand AI links Dr. Savvides to 15 clinical trials, 5 of them phase 2 studies. 3 are still active or recruiting. Conditions studied include Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell and Tongue Neoplasms. Case Comprehensive Cancer Center sponsors the most, 10. Open Payments lists research payments to Dr. Savvides that name 1 trial.

CMS Open Payments shows 330 general payments to Dr. Savvides from 28 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 51% of the total. Regeneron Pharmaceuticals, Inc. paid the most, $93,881. It also lists 3 research payments totaling $422 in 2023, naming 1 clinical trial.

Dr. Savvides graduated from University of Athens in 1986.

Dr. Savvides is in network with 5 carriers, including United Healthcare, Aetna and Blue Cross and Blue Shield of Kansas City. PPO plans come from the most carriers, 3. Check the plan with the practice before a visit.